Bolt Biotherapeutics (BOLT) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Corporate overview and financial position

• Expert team of over 50 employees focused on immunotherapy and cancer.

• Pipeline includes two proprietary products: BDC-3042 and BDC-4182.

• Nearly $100 million in cash, funding operations through mid-2026.

• No debt or warrants, maintaining a simple corporate structure.

Pipeline and clinical development

• BDC-3042 targets Dectin-2, in phase I dose escalation trial across seven solid tumor types.

• BDC-4182 targets Claudin 18.2, with clinical trials planned for 2025.

• BDC-3042 trial has reached cohort 6, showing safety and no dose-limiting toxicities.

• Early 2025 update planned on activity signals and next development steps.

Platform collaborations and partnerships

• Genmab collaboration explores bispecific technology with ISAC platform, potentially up to three programs.

• Toray partnership develops ISACs using their proprietary antibodies.

• Collaborations are fully funded by partners through early clinical proof of concept.